Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 309

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 309
---
 value of our cash equivalents and marketable securities as of the dates presented (in thousands):June 30, 2025Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$35,609 $— $— $35,609 Corporate debt securities1,550 — — 1,550 Marketable securities:U.S. treasury securities$51,865 $42 $(5)$51,902 Commercial paper50,563 5 (20)50,548 Corporate debt securities48,992 17 (4)49,005 U.S. government agency securities18,440 8 (4)18,444 Asset-backed securities2,013 — (1)2,012 Totals$209,032 $72 $(34)$209,070 December 31, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$17,693 $— $— $17,693 U.S. government securities999 — — 999 U.S. treasury securities997 — — 997 Marketable securities:Commercial paper$58,798 $56 $(31)$58,823 U.S. treasury securities46,231 80 (2)46,309 Corporate debt securities43,634 49 (14)43,669 U.S. government agency securities40,013 60 (2)40,071 Totals$208,365 $245 $(49)$208,561 The following table presents available-for-sale securities by contractual maturity date as of June 30, 2025 (in thousands):June 30, 2025Amortized CostEstimated Fair ValueDue in one year or less$157,218 $157,228 Due after one year14,655 14,683 Total$171,873 $171,911 As of June 30, 2025, fifty-one of the Company's marketable securities with a fair market value of $70.7 million were in an immaterial aggregate gross unrealized loss position; these fifty-one marketable securities have all been in a gross unrealized loss position for less than one year. Based on a review of these marketable securities, the Company believes